immunotherapy

Charles Manning, PhD, and colleagues are working to improve the effectiveness of immunotherapies earlier in treatment.
November 7, 2019

Project seeks new way to assess immunotherapy effectiveness

GE Healthcare has awarded researchers in the Vanderbilt University Institute of Imaging Science $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.

By Krystyna Barnard
August 22, 2019

New prostate cancer treatment concept

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

By Leigh MacMillan
July 22, 2019

Encephalitis identified as rare toxicity of immunotherapy treatment

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

By Tom Wilemon
June 18, 2019

Study identifies critical regulator of tumor-specific T cell differentiation

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work

By Tom Wilemon
June 6, 2019

Immunotherapy helping 87-year-old man stay on the job

Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.

By Tom Wilemon
February 28, 2019

VICC launches new telehealth program for CAR-T patients

Some cancer patients receiving CAR-T infusions can now avoid hospital stays because of a telemedicine program launched by Vanderbilt-Ingram Cancer Center.

By Tom Wilemon
February 21, 2019

Discovery points to new cancer immunotherapy option

An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
By Leigh MacMillan
January 7, 2019

GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment

GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies.
By VUMC News and Communications
December 13, 2018

Breast cancer-killing RIG

A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer.
By Leigh MacMillan
November 15, 2018

Immunotherapies linked to specific heart complications

In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
By Tom Wilemon
November 1, 2018

Team’s findings show glutamine metabolism affects T cell signaling

The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.
By Leigh MacMillan
October 25, 2018

Mary Kay Foundation grant to bolster immunotherapy research

An immunotherapy research initiative at Vanderbilt University Medical Center is among those being supported by the Mary Kay Foundation, which has announced $1.2 million in funding that will be equally shared among 12 cancer research institutions.
By Tom Wilemon
September 13, 2018

Study tracks incidence, timing of immunotherapy-related deaths

Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
By Tom Wilemon
1 2 3 4 5